1-3 of 3
Haresh Jhangiani, MD
Close
Sort by
Journal Articles

Preliminary Safety and Efficacy Results with an Intermittent Schedule of the PI3kδ Inhibitor ME-401 Alone or in Combination with Rituximab for B-Cell Malignancies

Andrew D. Zelenetz, MD PhD, Jacob D. Soumerai, MD, Deepa Jagadeesh, MD MPH, Nishitha Reddy, MD, Anastasios Stathis, MD, Adam S. Asch, MD, Huda S. Salman, MD, Vaishalee P. Kenkre, MD, Haresh Jhangiani, MD MBA, Alexia Iasonos, PhD, Patel Krish, MD, Richard G Ghalie, MD MBA, John M. Pagel, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2893.
https://doi.org/10.1182/blood-2018-99-115670
Published: 2018
Journal Articles

Rituximab Therapy after Response to R-CHOP Induction Therapy for Patients with Previously Untreated Indolent Non-Hodgkin’s Lymphoma (NHL): Clinical Outcomes and Pharmacokinetics (PK)

Louis Fehrenbacher, MD, Jonathan A. Polikoff, MD, Robert Hermann, MD, Haresh Jhangiani, MD, Jean Bjerke, MD, David Loeck, MD, Lowell Hart
Journal: Blood
Blood (2007) 110 (11): 1295.
https://doi.org/10.1182/blood.V110.11.1295.1295
Published: 2007
Journal Articles

Dronabinol or Ondansetron Alone and Combined for Delayed Chemotherapy-Induced Nausea and Vomiting (CINV).

Haresh Jhangiani, MD, James J. Vredenburgh, MD, Lou Barbato, MD, Haichen Yang, MD, Hwa-Ming Yang, PhD, Vickie Baranowski, Nielson Tse, MD
Journal: Blood
Blood (2005) 106 (11): 5555.
https://doi.org/10.1182/blood.V106.11.5555.5555
Published: 2005